Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why you should stop taking Vytorin for high cholesterol

Matthew Mintz, MD
Meds
November 16, 2009
7 Shares
Share
Tweet
Share

At the American Heart Association meeting in Orlando, the results of the ARBITER 6-HALTS study were released. No Vytorin was used in the study, but I am sure that all the headlines will mention Vytorin.

The actual study published ahead of press online in the New England Journal of Medicine. Essentially, they enrolled over 200 patients from Walter Reed and Washington Adventist who had known heart disease or were at very high risk. These patients were already on a stable dose of a statin (40-50% on simvastatin – half of the Vytorin combination, and 40-50% on Lipitor) with an LDL cholesterol (bad cholesterol) under 100 and HDL (good cholesterol) under 50 for men/55 for women. These patients were randomized to receive either Zetia (the other half of Vytorin) or niacin (though you can get this vitamin over the counter, patients received the extended release prescription version, whose maker is also the sponsor of the study).

They were looking to see whether or not there would be difference in progression of atherosclerosis (clogging of the arteries) over 14 months as measured by carotid intima-medial thickness (CIMT), and ultrasound of the neck arteries which seems to be a good measure of plaque buildup in the coronary or heart arteries. News broke earlier this year that the study was stopped early because there was a clear winner, but we didn’t know which drug won until now.

Patients who got the niacin had their good cholesterol raised by close to 20%. bad cholesterol lowered by close to 10%. The Zetia group lowered bad cholesterol by close to 20% but also lowered the good cholesterol too. More importantly, those patients taking the niacin had a reduction in the plaque buildup, whereas patients taking the Zetia had no change in plaque build up. Surprisingly, and inexplicably, the more Zetia lowered your cholesterol, the more plaque build up patients had. Finally, and most importantly, only 1% of patients in the niacin group had major cardiovascular events, compared to 4% in the Zetia groups. This was statistically significant.

This trial has broader implications than just the Vytorin issue. It suggests that patients at high risk for cardiovascular disease may have additional benefit beyond lowering their bad cholesterol. Though the addition of niacin was proven to show benefit, it might be possible that other drugs which raise HDL such as fish oil and fenofibrate (Trilipix) might benefit at risk patients as well.

I have posted extensively on Vytorin in the past. Most of the controversy had to do with the ENHANCE trial which I discussed in my post Vytorin and Zetia: What to do now?

Briefly, whereas multiple statin trials have shown that lowering LDL with a statin led to decreased heart attacks and stroke, Vytorin only had data showing it lowered the LDL. Merck, the makers of Zocor (simvastatin), Zetia, and Vytorin (Zocor + Zetia) funded a trial that, similar to the HALT study, looked at CIMT to measure plaque buildup. It compared simvastatin to the same dose of simvastatin plus Zetia, or Vytorin. Though Vytorin lowered cholesterol more that the simvastatin alone, there was no difference in plaque buildup.

Defenders of Vytorin said that ENHANCE was not an outcome study (designed to study actual heart attacks and strokes) and that there were no differences in outcomes between the two groups. Though the HALT study was also not designed as an outcome study, findings were consistent AND there was a difference in heart attacks and strokes: about triple the number in the Vytorin group.

My initial recommendation was that though Vytorin was really useless, if patients couldn’t reach their goal with a potent statin or couldn’t tolerate the statin, then using or adding Zetia was reasonable. This is probably still the case. However, in the HALT study differences were seen in HDL (went up for niacin and down for Zetia), and this may account for some of the difference. For patients whose HDL was low, I will probably be a little more cautious of using or adding Zetia, which may make their HDL go down in addition to their LDL.

There is no good use for Vytorin, and it may even cause harm, not because of safety, but because the LDL goals achieved with Vytorin may lead to fewer heart attacks that could be prevented with a more potent statin. If you are on Vytorin, ask you doctor about considering a switch.

Matthew Mintz is an internal medicine physician and blogs at Dr. Mintz’ Blog.

Submit a guest post and be heard.

Prev

Niacin beats Zetia in the ARBITER 6-HALTS trial, and what this means for ezetimibe

November 16, 2009 Kevin 2
…
Next

Learn how to conduct a family meeting by using a structured approach

November 16, 2009 Kevin 1
…

Tagged as: Cardiology, Medications, Patients, Primary Care, Specialist

Post navigation

< Previous Post
Niacin beats Zetia in the ARBITER 6-HALTS trial, and what this means for ezetimibe
Next Post >
Learn how to conduct a family meeting by using a structured approach

More by Matthew Mintz, MD

  • a desk with keyboard and ipad with the kevinmd logo

    Primary care trends in the health reform era

    Matthew Mintz, MD
  • a desk with keyboard and ipad with the kevinmd logo

    IVIG for Alzerheimer’s: Cost is a barrier

    Matthew Mintz, MD
  • a desk with keyboard and ipad with the kevinmd logo

    Is there a harm to not seeing drug reps?

    Matthew Mintz, MD

More in Meds

  • Drug prices and fast approvals can harm patients

    Martha Rosenberg
  • Are clinicians complicit in the Fentanyl epidemic?

    Janet Tamaren, MD
  • Will GLP-1s allow our society to eschew its responsibility to create a healthy environment?

    Monica Ball-Zondervan, MD
  • Can ketamine and SSRIs offer a complete depression treatment?

    L. Joseph Parker, MD
  • Cannabis compounds in fracture pain relief and healing

    L. Joseph Parker, MD
  • Codeine cough syrup: a controversial classification

    L. Joseph Parker, MD
  • Most Popular

  • Past Week

    • Pain medicine realities: beyond the opioid crisis

      Richard A. Lawhern, PhD and Stephen E. Nadeau, MD | Conditions
    • There’s no place for “benevolent deception” in obstetrics

      Megan Nix | Conditions
    • New primary care decision support tools make offloading below-license tasks from the EHR more important than ever

      Jeffrey H. Millstein, MD | Tech
    • The brain science behind acupuncture

      Marc Arginteanu, MD | Conditions
    • Emotional freedom and resilience: a family physician’s inspiring journey [PODCAST]

      The Podcast by KevinMD | Podcast
    • Job stacking for doctors: a modern approach to work-life balance

      Tod Stillson, MD | Finance
  • Past 6 Months

    • Gaza’s medical crisis

      Tammy Abughnaim, MD and Emily Hacker, MPH | Physician
    • Medicare coverage saves lives. Enrolling shouldn’t be this complicated.

      Catherine L. Chen, MD, MPH | Physician
    • Antisemitism is at a historic high not just in other countries, but right here in America

      Joshua D. Lenchus, DO | Physician
    • Medicine has become the new McDonald’s of health care

      Arthur Lazarus, MD, MBA | Policy
    • Emergency department burnout: a cry for change

      Anonymous | Conditions
    • Rising nurse practitioner burnout: charting and work-life balance

      Erica Dorn, FNP | Conditions
  • Recent Posts

    • New primary care decision support tools make offloading below-license tasks from the EHR more important than ever

      Jeffrey H. Millstein, MD | Tech
    • Physician burnout reimagined

      Claudia Finkelstein, MD | Physician
    • A mother’s healing love song

      Ana María Caballero | Conditions
    • Government surveillance: How electronic prescription records are changing medicine

      L. Joseph Parker, MD | Physician
    • Intensive caring: Reminding patients they matter

      Harvey Max Chochinov, MD, PhD | Physician
    • Navigating COVID: Why it still matters

      Anu Osinusi, MD, MPH & The Podcast by KevinMD | Podcast, Sponsored

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Common Headaches May Be Pains in the Neck
  • Methotrexate Tied to Greater Risks for Older Patients With CKD
  • FDA Warns of Rare Life-Threatening Reaction to Anti-Seizure Drugs
  • Texas Abortion Case Spotlights Issues Around Medical Exceptions to Abortion Bans
  • Stephen Colbert Has Surgery for Ruptured Appendix

Meeting Coverage

  • Common Headaches May Be Pains in the Neck
  • Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer
  • Simplified Assessment Tool for Psoriatic Arthritis Performs Well
  • Biologic Therapy for IBD Not Tied to Higher Risk of Major Heart Events
  • COVID Tied to Changes in Brain Microstructure
  • Most Popular

  • Past Week

    • Pain medicine realities: beyond the opioid crisis

      Richard A. Lawhern, PhD and Stephen E. Nadeau, MD | Conditions
    • There’s no place for “benevolent deception” in obstetrics

      Megan Nix | Conditions
    • New primary care decision support tools make offloading below-license tasks from the EHR more important than ever

      Jeffrey H. Millstein, MD | Tech
    • The brain science behind acupuncture

      Marc Arginteanu, MD | Conditions
    • Emotional freedom and resilience: a family physician’s inspiring journey [PODCAST]

      The Podcast by KevinMD | Podcast
    • Job stacking for doctors: a modern approach to work-life balance

      Tod Stillson, MD | Finance
  • Past 6 Months

    • Gaza’s medical crisis

      Tammy Abughnaim, MD and Emily Hacker, MPH | Physician
    • Medicare coverage saves lives. Enrolling shouldn’t be this complicated.

      Catherine L. Chen, MD, MPH | Physician
    • Antisemitism is at a historic high not just in other countries, but right here in America

      Joshua D. Lenchus, DO | Physician
    • Medicine has become the new McDonald’s of health care

      Arthur Lazarus, MD, MBA | Policy
    • Emergency department burnout: a cry for change

      Anonymous | Conditions
    • Rising nurse practitioner burnout: charting and work-life balance

      Erica Dorn, FNP | Conditions
  • Recent Posts

    • New primary care decision support tools make offloading below-license tasks from the EHR more important than ever

      Jeffrey H. Millstein, MD | Tech
    • Physician burnout reimagined

      Claudia Finkelstein, MD | Physician
    • A mother’s healing love song

      Ana María Caballero | Conditions
    • Government surveillance: How electronic prescription records are changing medicine

      L. Joseph Parker, MD | Physician
    • Intensive caring: Reminding patients they matter

      Harvey Max Chochinov, MD, PhD | Physician
    • Navigating COVID: Why it still matters

      Anu Osinusi, MD, MPH & The Podcast by KevinMD | Podcast, Sponsored

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why you should stop taking Vytorin for high cholesterol
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...